Condition: Obesity · Vascular Health · Sponsor: VA Office of Research and Development
The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.
This description comes directly from the study's public registry record.
Jaume Padilla Parellada, PhD · (573) 814-6552 · jaume.padillaparellada@va.gov
Katherine M Burr · (573) 814-6550 · Katherine.Burr@va.gov
Always discuss trial participation with your own doctor first.
| Harry S. Truman Memorial, Columbia, MO | Columbia, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06745063